A novel mouse model of TDP-43 Proteinopathy in FTLD-ALS: Elucidating the role of TDP-43 acetylation in neurodegeneration and proteostasis impairment

FTLD-ALS 中 TDP-43 蛋白病的新型小鼠模型:阐明 TDP-43 乙酰化在神经变性和蛋白质稳态损伤中的作用

基本信息

项目摘要

Project Summary Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are two progressive neurodegenerative disorders on a spectrum of disease related to the RNA/DNA binding protein TAR DNA- binding Protein of 43 kDa (TDP-43). Many patients demonstrate an intermediate phenotype of dementia with motor neuron disease (here called FTLD-ALS). The vast majority of pure FTLD and ALS cases are sporadic (sFTLD, sALS), with no family history or known genetic mutation. More than 50% of all FTLD and 90% of all ALS cases manifest a characteristic pathology in affected neurons: hyperphosphorylated, ubiquitinated inclusions of TDP-43. TDP-43 pathology is often observed in other neurodegenerative disorders, including Alzheimer’s and Parkinson’s Diseases, suggesting a common pathogenic mechanism linking TDP-43 dysfunction and neurodegeneration. TDP-43 aggregates are normally degraded by autophagy, but in FTLD-ALS this machinery fails, contributing to disease progression. In fact, some familial FTLD-ALS cases are caused by mutations in autophagy-related proteins. The mechanisms behind TDP-43 aggregation and the neurotoxicity it imparts remain poorly understood, particularly in sporadic disease. Most animal models rely on overexpression of disease- associated genetic variants; however, these may be limited in generalizability to sporadic disease. Our lab identified TDP-43 acetylated at a key lysine residue (Ac-K145) as a driver of TDP-43 pathology. Ac-K145 TDP- 43 is detected in the pathologic inclusions in sALS spinal cord. With the goal of better modeling sporadic illness, we used CRISPR/Cas9 technology to insert a K145Q acetylation-mimic mutation in the endogenous mouse Tardbp locus (TDP-43K145Q) to generate a novel model of TDP-43 proteinopathy in sporadic FTLD-ALS. TDP- 43K145Q mice show hallmark pathologies, such as age-dependent cognitive impairment and accumulation of insoluble TDP-43 in the cortex and spinal cord. This project aims to determine the role of acetylation-mimic TDP- 43 in neurodegeneration and autophagy impairment. Aim 1 will test the hypothesis that aging exacerbates the neurodegenerative phenotype in TDP-43K145Q mice, using behavioral assays of cognitive and motor function, neuropathologic assessment of cortical tissue, and electrodiagnostic studies of motor unit function. Aim 2 will test the hypothesis that autophagic flux is impaired in primary cortical neurons of TDP-43K145Q sFTLD-ALS mice, using an in vitro aging paradigm alongside pharmacologic manipulation of autophagy and biochemical and live- cell imaging techniques. The long-term goal of this project is to better understand the mechanisms behind TDP- 43-related neurodegeneration and reveal opportunities for therapeutic intervention. This work will provide me with comprehensive training in both translational and basic science research methods, and I will complement my research with mentored clinical activities caring for neurodegenerative disease patients. The top-tier research and clinical opportunities available at UNC Chapel Hill, alongside my mentor, Dr. Todd Cohen, and expert collaborators, will help launch my career as a leading physician-scientist in neurodegenerative disease biology.
项目摘要 额颞叶变性(FTLD)和肌萎缩侧索硬化症(ALS)是两种进行性 神经退行性疾病对与RNA/DNA结合蛋白TAR DNA相关的疾病谱的影响- 43 kDa结合蛋白(TDP-43)。许多患者表现出痴呆的中间表型, 运动神经元疾病(这里称为FTLD-ALS)。绝大多数纯FTLD和ALS病例是散发的 (sFTLD,sALS),没有家族史或已知的基因突变。超过50%的FTLD和90%的ALS 例表现出受影响的神经元的特征性病理:过度磷酸化,泛素化的包涵体, TDP-43 TDP-43病理学通常在其他神经退行性疾病中观察到,包括阿尔茨海默病和阿尔茨海默病。 帕金森氏病,表明一种共同的致病机制,连接TDP-43功能障碍和 神经变性TDP-43聚集体通常通过自噬降解,但在FTLD-ALS中,这种机制 失败,导致疾病进展。事实上,一些家族性FTLD-ALS病例是由以下突变引起的: 自噬相关蛋白SDP-43聚集及其赋予的神经毒性背后的机制仍然存在 我们对此知之甚少,尤其是在散发性疾病中。大多数动物模型依赖于疾病的过度表达- 相关的遗传变异;然而,这些可能局限于散发性疾病的普遍性。我们实验室 鉴定了在关键赖氨酸残基(Ac-K145)处乙酰化的TDP-43作为TDP-43病理学的驱动因素。Ac-K145 TDP- 43在sALS脊髓的病理包涵体中检测到。为了更好地模拟散发性疾病, 我们使用CRISPR/Cas9技术在内源性小鼠中插入K145 Q乙酰化模拟突变, Tardbp基因座(TDP-43 K145 Q),以产生散发性FTLD-ALS中TDP-43蛋白质病的新模型。TDP- 43 K145 Q小鼠表现出标志性病理学,如年龄依赖性认知障碍和 不溶性TDP-43在皮质和脊髓中。该项目旨在确定乙酰化模拟TDP的作用, 43例神经变性和自噬损伤。目标1将检验衰老加剧 TDP-43 K145 Q小鼠的神经退行性表型,使用认知和运动功能的行为测定, 皮质组织的神经病理学评估和运动单位功能的电诊断研究。目标2将 检验TDP-43 K145 Q sFTLD-ALS小鼠的原代皮层神经元中自噬通量受损的假设, 使用体外衰老范例以及自噬和生物化学和活体的药理学操作, 细胞成像技术。该项目的长期目标是更好地了解TDP背后的机制- 43-相关的神经变性,并揭示治疗干预的机会。这项工作将为我提供 在转化和基础科学研究方法的全面培训,我将补充我的 研究与指导临床活动照顾神经退行性疾病患者。顶级研究 和临床的机会,可在圣查佩尔山,旁边我的导师,博士托德科恩,和专家 合作者,将有助于启动我的职业生涯作为一个领先的医生,科学家在神经退行性疾病生物学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julie Christine Necarsulmer其他文献

Julie Christine Necarsulmer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julie Christine Necarsulmer', 18)}}的其他基金

A novel mouse model of TDP-43 Proteinopathy in FTLD-ALS: Elucidating the role of TDP-43 acetylation in neurodegeneration and proteostasis impairment
FTLD-ALS 中 TDP-43 蛋白病的新型小鼠模型:阐明 TDP-43 乙酰化在神经变性和蛋白质稳态损伤中的作用
  • 批准号:
    10663240
  • 财政年份:
    2021
  • 资助金额:
    $ 3.89万
  • 项目类别:
A novel mouse model of TDP-43 Proteinopathy in FTLD-ALS: Elucidating the role of TDP-43 acetylation in neurodegeneration and proteostasis impairment
FTLD-ALS 中 TDP-43 蛋白病的新型小鼠模型:阐明 TDP-43 乙酰化在神经变性和蛋白质稳态损伤中的作用
  • 批准号:
    10231513
  • 财政年份:
    2021
  • 资助金额:
    $ 3.89万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 3.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了